☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Acadia Pharmaceuticals
Acadia Pharmaceuticals Reports P-III (ADVANCE-2) Study Results of Pimavanserin to Treat Negative Schizophrenia Symptoms
March 13, 2024
Acadia Pharmaceuticals Reports P-III Study (LAVENDER) Results of Daybue (trofinetide) for the Treatment of Rett Syndrome
June 10, 2023
Acadia Pharmaceuticals Launches Daybue (trofinetide) for the Treatment of Rett Syndrome in the US
April 18, 2023
Acadia’s Daybue (trofinetide) Receives the US FDA’s Approval for Rett Syndrome in Adult and Pediatric Patients Aged ≥2Years
March 13, 2023
Top 20 Biopharma M&A of 2020 by Total Deal Value
January 7, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.